Senti Biosciences Inc (SNTI) Stock Price, Quote & News

Company Profile

Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. It offers SENTI-202, a logic gated off-the-shelf CAR-NK cell thera...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 239 2030

Website: www.sentibio.com

Address:

2 Corporate Drive, First Floor, South San Francisco, United States

AskDaly Jun. 8 at 3:09 PM

$KALA “Palantir for biotech.” Tiny market cap, AI narrative, and retail attention starting to build. Worth keeping on the watchlist. Nice zone to bid/buy - accumulating * $BURU * $ONDS * $SNTI

0 · Reply

EdV3 May. 30 at 8:05 PM

$SNTI

0 · Reply

nextrated May. 21 at 2:45 PM

$SNTI In

0 · Reply

topstockalerts May. 20 at 6:49 PM

$SNTI dollar push ahead?

0 · Reply

finansbull88 May. 20 at 6:23 PM

$ONCO Also buy Silexion Therapeutics Corp $SLXN while it's under the radar. This stock has 5000% upside and is completely mispriced. $MTVA $SNTI

1 · Reply

SuperGreenToday May. 19 at 8:36 AM

$SNTI

0 · Reply

anachartanalyst May. 15 at 5:02 PM

$SNTI https://anachart.com/wp-content/uploads/2026/05/1778864505_soc-img.jpg

1 · Reply

Be4real May. 15 at 12:54 PM

$SNTI Before it was 4.00 PT, now 12.00! What does that tell you?

2 · Reply

EdV3 May. 14 at 5:44 PM

$SNTI bullish update. data continues to impress and the post hoc donor x finding could mean even better overall data on the trial. single arm confirmed. money from Celadon should get them at least to say 25% enrollment maybe more. Peak we sales if approved could be over $1BN not including pediatric AML or newly diagnosed or earlier treatment.

0 · Reply

buttercup1007 May. 14 at 2:45 PM

$SNTI from .97 hit 1.06, still has steam. Volume rising

0 · Reply

Senti Bio completes Type B RMAT meeting with FDA on SENTI-202

May 14, 2026, 9:00 AM EDT - 25 days ago

Senti Biosciences Holdings Earnings release: Q1 2026

May 14, 2026, 9:00 AM EDT - 25 days ago

Senti Biosciences Holdings Quarterly report: Q1 2026

May 14, 2026, 8:45 AM EDT - 25 days ago

Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase

$Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program$

May 14, 2026, 8:40 AM EDT - 25 days ago

Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program

Apr 13, 2026, 9:00 AM EDT - 2 months ago

Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026

Apr 9, 2026, 7:00 AM EDT - 2 months ago

Senti Biosciences Holdings Slides: Corporate presentation

Apr 1, 2026, 8:45 AM EDT - 2 months ago

Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies

Mar 27, 2026, 8:00 AM EDT - 2 months ago

Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

Mar 27, 2026, 8:00 AM EDT - 2 months ago

Senti Biosciences Holdings Annual report: Q4 2025

Mar 27, 2026, 8:00 AM EDT - 2 months ago

Senti Biosciences Holdings Earnings release: Q4 2025

Mar 23, 2026, 9:00 AM EDT - 2 months ago

Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference

Mar 9, 2026, 2:20 PM EDT - 3 months ago

Senti Biosciences Holdings Transcript: Leerink Global Healthcare Conference 2026

Mar 3, 2026, 9:05 AM EST - 3 months ago

Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference

Mar 2, 2026, 3:10 PM EST - 3 months ago

Senti Biosciences Holdings Transcript: TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 9:15 AM EST - 3 months ago

Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference

Feb 20, 2026, 8:50 AM EST - 3 months ago

Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development

2026-02-11T13:40:59.000Z - 4 months ago

Senti Bio completes enrollment in Phase 1 trial of SENTI-202

$Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)$

Feb 11, 2026, 8:35 AM EST - 4 months ago

Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

Feb 3, 2026, 9:00 AM EST - 4 months ago

Senti Biosciences Selected for On-Stage Presentation at Healthcare Conference Taipei 2026

Jan 14, 2026, 9:15 AM EST - 5 months ago

Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company's Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation

Jan 9, 2026, 8:55 AM EST - 5 months ago

Senti Bio to Participate in Panel Presentation at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference

Dec 18, 2025, 5:30 PM EST - 6 months ago

Senti Biosciences Announces New Employment Inducement Grants

2025-12-09T18:55:12.000Z - 6 months ago

Senti Bio price target raised to $13 from $12 at Chardan

2025-12-09T13:23:07.000Z - 6 months ago

Why Is Senti Biosciences Stock (SNTI) Up Today?

Dec 9, 2025, 8:00 AM EST - 6 months ago

Senti Biosciences Holdings Transcript: Study Update

Dec 9, 2025, 8:00 AM EST - 6 months ago

Senti Biosciences Holdings Press release: Study Update

Dec 9, 2025, 8:00 AM EST - 6 months ago

Senti Biosciences Holdings Slides: Study Update

2025-12-09T12:11:51.000Z - 6 months ago

Senti Bio receives FDA RMAT designation for SENTI-202

2025-12-09T12:11:34.000Z - 6 months ago

Senti Bio announces new data from trial of SENTI-202

$Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for SENTI-202 in the Treatment of Adults with Relapsed or Refractory Acute Myeloid Leukemia$

Dec 9, 2025, 7:00 AM EST - 6 months ago

Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for SENTI-202 in the Treatment of Adults with Relapsed or Refractory Acute Myeloid Leukemia

$Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile$

Dec 9, 2025, 7:00 AM EST - 6 months ago

Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile

Dec 4, 2025, 8:45 AM EST - 6 months ago

Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Society of Hematology (ASH) Annual Meeting 2025 on Tuesday, December 9th at 8:00 AM ET

2025-11-21T13:30:16.000Z - 7 months ago

Senti Bio initiated with an Outperform at Leerink

Nov 13, 2025, 4:30 PM EST - 7 months ago

Senti Bio Reports Third Quarter 2025 Financial Results and Confirms Next Clinical Data Readout for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) at the American Society of Hematology Annual Meeting in December

Nov 13, 2025, 12:00 AM EST - 7 months ago

Senti Biosciences Holdings Quarterly report: Q3 2025

Nov 13, 2025, 12:00 AM EST - 7 months ago

Senti Biosciences Holdings Earnings release: Q3 2025

Nov 3, 2025, 9:05 AM EST - 7 months ago

Senti Bio to Present Updated Clinical Results of First-in-Class Logic Gated CD33/FLT3 Cell Therapy, SENTI-202, at the American Society of Hematology (ASH) Annual Meeting 2025

Oct 21, 2025, 11:35 AM EDT - 8 months ago

Senti Biosciences Holdings Transcript: Chardan’s 9th Annual Genetic Medicines Conference

Oct 16, 2025, 9:05 AM EDT - 8 months ago

Senti Bio to Present at Chardan's 9th Annual Genetic Medicines Conference

2025-10-14T10:15:37.000Z - 8 months ago

Senti Bio initiated with a Buy at H.C. Wainwright

Oct 6, 2025, 9:05 AM EDT - 8 months ago

Senti Bio to Present at BioJapan

Sep 24, 2025, 12:55 PM EDT - 9 months ago

Senti Biosciences Holdings Transcript: MedInvest Biotech & Pharma Conference

Sep 18, 2025, 9:15 AM EDT - 9 months ago

Senti Bio to Present at the MedInvest Biotech & Pharma Conference

Sep 8, 2025, 2:00 PM EDT - 9 months ago

Senti Biosciences Holdings Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 9:00 AM EDT - 9 months ago

Senti Biosciences Holdings Slides: Corporate Presentation

Sep 2, 2025, 9:05 AM EDT - 9 months ago

Senti Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 14, 2025, 9:15 AM EDT - 10 months ago

Senti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

2025-08-12T13:20:47.000Z - 10 months ago

Senti Bio releases virtual “What This Means” segment

Aug 12, 2025, 9:15 AM EDT - 10 months ago

Senti Bio Participates in Virtual Investor “What This Means” Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia

Aug 7, 2025, 8:05 AM EDT - 10 months ago

Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025

Aug 7, 2025, 7:00 AM EDT - 10 months ago

Senti Biosciences Holdings Earnings release: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 10 months ago

Senti Biosciences Holdings Quarterly report: Q2 2025

2025-08-05T12:51:08.000Z - 10 months ago

Senti Bio confirms recommended RP2D in Phase 1 study of SENTI-202

$Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia$

Aug 5, 2025, 8:30 AM EDT - 10 months ago

Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia

Jul 22, 2025, 8:45 AM EDT - 11 months ago

Senti Biosciences Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 21, 2025, 8:55 AM EDT - 11 months ago

Senti Bio's Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give Feature Presentation at the BioScience Forum

2025-07-18T13:00:24.000Z - 11 months ago

Senti Bio appoints Bryan Baum to board of directors

Jul 18, 2025, 8:55 AM EDT - 11 months ago

Senti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of Directors

2025-06-30T14:55:33.000Z - 1 year ago

Senti Bio participates in Nasdaq Amplify Spotlight Series

Jun 30, 2025, 9:15 AM EDT - 1 year ago

Senti Bio Participates in Nasdaq Amplify Spotlight Series

Jun 24, 2025, 8:45 AM EDT - 1 year ago

Senti Bio to Present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference

2025-06-18T11:06:02.000Z - 1 year ago

Senti Bio announces U.S. FDA granted ODD to SENTI-202

Jun 18, 2025, 7:00 AM EDT - 1 year ago

Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia

Jun 6, 2025, 9:05 AM EDT - 1 year ago

Senti Bio to Participate in a Virtual Fireside Chat Hosted by Chardan Capital Markets, LLC

2025-06-06T09:00:30.000Z - 1 year ago

Senti Bio initiated with a Buy at Laidlaw

May 29, 2025, 2:40 PM EDT - 1 year ago

Senti Biosciences Holdings Transcript: Webull Corporate Connect: Virtual Biotech Investment Webinar

May 22, 2025, 4:05 PM EDT - 1 year ago

Senti Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

2025-05-22T12:41:22.000Z - 1 year ago

Senti Bio receives additional $1M tranche from CIRM grant

May 22, 2025, 8:30 AM EDT - 1 year ago

Senti Bio Receives Additional $1.0 Million Tranche from California Institute for Regenerative Medicines (CIRM) Grant for Advancing Clinical Development of SENTI-202

AskDaly Jun. 8 at 3:09 PM

$KALA “Palantir for biotech.” Tiny market cap, AI narrative, and retail attention starting to build. Worth keeping on the watchlist. Nice zone to bid/buy - accumulating * $BURU * $ONDS * $SNTI

0 · Reply

EdV3 May. 30 at 8:05 PM

$SNTI

0 · Reply

nextrated May. 21 at 2:45 PM

$SNTI In

0 · Reply

topstockalerts May. 20 at 6:49 PM

$SNTI dollar push ahead?

0 · Reply

finansbull88 May. 20 at 6:23 PM

$ONCO Also buy Silexion Therapeutics Corp $SLXN while it's under the radar. This stock has 5000% upside and is completely mispriced. $MTVA $SNTI

1 · Reply

SuperGreenToday May. 19 at 8:36 AM

$SNTI

0 · Reply

anachartanalyst May. 15 at 5:02 PM

$SNTI https://anachart.com/wp-content/uploads/2026/05/1778864505_soc-img.jpg

1 · Reply

Be4real May. 15 at 12:54 PM

$SNTI Before it was 4.00 PT, now 12.00! What does that tell you?

2 · Reply

EdV3 May. 14 at 5:44 PM

0 · Reply

buttercup1007 May. 14 at 2:45 PM

$SNTI from .97 hit 1.06, still has steam. Volume rising

0 · Reply

buttercup1007 May. 14 at 2:22 PM

$SNTI good.earning and is moving up steadily. Could see 1.20 ?

0 · Reply

CHItraders May. 14 at 12:50 PM

📊 Senti Biosciences $SNTI Q1 Earnings ✅ Earnings Beat Adj. EPS: $(0.14) YoY: ↑ 90.07% (from $(1.41)) 🔹 Sales: $16.000K

0 · Reply

TwongStocks May. 14 at 12:46 PM

$SNTI Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase https://investors.sentibio.com/news-releases/news-release-details/senti-biosciences-holdings-reports-first-quarter-2026-financial

0 · Reply

OpenOutcrier May. 14 at 12:44 PM

$SNTI (+3.1% pre) Senti Bio receives FDA guidance for SENTI-202 registrational trial https://ooc.bz/l/102309

0 · Reply

EdV3 May. 14 at 2:31 AM

$SNTI dead money.....until it's not?

0 · Reply

Moneypa May. 9 at 10:22 PM

$SNTI senti might benefit from this, am expecting some new INDs to be filed, pediatric and new aml. https://www.livescience.com/health/some-gene-therapies-no-longer-require-clinical-trials-thanks-to-new-fda-rule-is-this-safe-and-who-will-it-help

0 · Reply

EdV3 May. 8 at 5:08 PM

$SNTI non zero chance celadon turns this into an ai or data center company 😂

0 · Reply

EdV3 May. 7 at 1:42 AM

$SNTI I think this might just be pinned around $1 for the foreseeable future. The financing deal is too cloudy and leaves only marginal upside to common shareholders. Hoping for some more clarity in the coming quarter.

0 · Reply

Moneypa May. 5 at 2:33 AM

$SNTI https://podcasts.apple.com/sg/podcast/how-senti-bios-programmable-cell-therapy-tackles-amls/id923189836?i=1000746876432

0 · Reply

EdV3 May. 4 at 12:56 AM

$SNTI I wonder what Bayer thinks of this financing deal. They have a large ownership percentage. Bluerock therapeutics, with whom Senti have an active collaboration with, are a wholly under subsidiary of Bayer as well. Is there a lifeline out there from them via a partnership or acquisition before this predatory second tranche closes? Not my base case by any means but hardly impossible.

1 · Reply

TwongStocks May. 1 at 8:13 PM

$SNTI Agreed to enter into a $40M convertible note agreement with Celadon https://www.sec.gov/ix?doc=/Archives/edgar/data/0001854270/000162828026029320/snti-20260427.htm 1st tranche is $10M 2nd tranche is $30M

1 · Reply

buttercup1007 May. 1 at 2:05 PM

$SNTI hello

0 · Reply

Market Cap	35.50M
Revenue (ttm)	20,000.00
Net Income (ttm)	-61.44M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-307,200.00%
Debt to Equity Ratio	0.00

Volume	177,818
Avg Vol	152,448
Day's Range	N/A - N/A
Shares Out	31.14M
Stochastic %K	42%
Beta	2.11
Analysts	Strong Sell
Price Target	$9.67